Condition: Kidney Transplant Failure and Rejection · Immunosuppression-related Infectious Disease · Sponsor: University Hospital, Grenoble
This prospective study will investigate the concentrations of tacrolimus metabolites (M-I and M-III) over the four first years post-transplantation. A differential metabolism might result in different metabolites' concentration and explain a kidney survival difference between "high rate metabolism" (defined as a concentration/dose ratio, C/D ratio, lower than 1.04 µg/l/mg) and other patients. The primary endpoint is therefore to compare tacrolimus metabolites' concentrations with respect to the group, either \< or \>= 1.04 µg/l/mg, in order to detect differences in tacrolimus metabolization between these groups.
This description comes directly from the study's public registry record.
Thomas JOUVE, MD, PhD · +33476765460 · tjouve@chu-grenoble.fr
Johan NOBLE, MD · +33476765460 · jnoble@chu-grenoble.fr
Always discuss trial participation with your own doctor first.
| Grenoble University Hospital | Grenoble, Auvergne-Rhône-Alpes, France | Recruiting |
| Saint Etienne University Hospital | Saint-Etienne, Auvergne-Rhône-Alpes, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04526431